Divi’s Laboratories Issues FY26 Dividend TDS Communication; Shares Trade Flat

Mumbai, June 12: Divi’s Laboratories informed shareholders regarding tax deduction at source (TDS) procedures applicable to dividend payments for the financial year 2025-26.

The company said it has sent a detailed communication to shareholders whose email addresses are registered with the company or depositories, outlining documentation and compliance requirements linked to dividend taxation.

According to the communication, the Board of Directors had earlier recommended a final dividend of ₹30 per fully paid-up equity share of face value ₹2 each for FY26.

The proposed dividend remains subject to shareholder approval at the company’s 36th Annual General Meeting scheduled for August 10, 2026.

Divi’s Laboratories stated that the record date for determining shareholder eligibility for the dividend has been fixed as July 24, 2026.

The company also outlined procedures related to lower withholding tax certificates, PAN-Aadhaar linkage compliance, DTAA benefits for non-resident shareholders and submission timelines for tax exemption documentation.

As per the shareholder note, dividend payments, if approved at the AGM, are expected to be distributed after August 14, 2026.

Stock Market Snapshot

Divi’s Laboratories share price traded largely flat following the shareholder communication regarding dividend taxation procedures.

The stock traded at ₹6,650.50, down 0.075%, as of 10:02 IST on June 12, 2026.

Divi’s Laboratories share price witnessed mild weakness during the morning session, broadly in line with muted movement across select pharmaceutical counters.

The communication is procedural in nature and relates to statutory shareholder compliance requirements ahead of the proposed dividend payout.

Investors continue to monitor dividend announcements and payout timelines across large-cap pharmaceutical companies amid ongoing earnings and capital allocation discussions.

Shareholders Asked To Submit Tax Documents Before Cut-Off

The company advised eligible shareholders seeking lower or nil tax deduction to submit required forms and declarations before July 24, 2026.

Resident shareholders may submit Form 15G or Form 15H, subject to eligibility conditions, while non-resident investors may furnish tax residency certificates and other supporting documents to avail DTAA-related benefits.

Divi’s Laboratories also highlighted that tax may be deducted at higher rates in cases involving invalid or non-linked PAN details under applicable Income-tax Act provisions.

The company added that shareholders can upload tax-related documents through designated online portals managed in coordination with KFin Technologies.

Company Background

Divi’s Laboratories Ltd is a pharmaceutical manufacturing company engaged in active pharmaceutical ingredients (APIs), intermediates and custom synthesis operations for global pharmaceutical clients.

The company operates manufacturing facilities in India and supplies products across regulated international markets.

Conclusion

The latest communication from Divi’s Laboratories relates to shareholder compliance and tax documentation procedures tied to the proposed FY26 dividend payout.

While the update does not materially alter business operations, investors are likely to monitor dividend approval timelines and related shareholder actions ahead of the AGM scheduled in August 2026.

Source:

• https://www.nseindia.com/get-quote/equity/DIVISLAB/Divi’s-Laboratories-Limited
• https://nsearchives.nseindia.com/corporate/DIVISLAB_11062026091018_Intimation_about_TDS_deduction_on_dividend.pdf